Aveanna director Erica Schwartz resigns for CDC role
Aveanna Healthcare Holdings Inc. announced that on August 5, 2026, Dr. Erica Schwartz, a Class III, independent director, resigned from its Board of Directors, effective immediately.
Rhea-AI Filing Summary
Aveanna Healthcare Holdings Inc. announced that on August 5, 2026, Dr. Erica Schwartz, a Class III, independent director, resigned from its Board of Directors, effective immediately. Her departure is tied to her nomination and subsequent confirmation as Director of the United States Centers of Disease Control and Prevention.
The company states that Dr. Schwartz’s resignation was not due to any disagreement regarding its operations, policies, or practices. Before stepping down, she served as Chair of the Clinical Quality Committee, providing board-level oversight of clinical quality matters.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Resignation date: August 5, 2026
Report signature date: August 7, 2026
Par value per share: $0.01 per share
3 metrics
Resignation date
August 5, 2026
Date Dr. Erica Schwartz resigned from Aveanna Healthcare’s Board of Directors
Report signature date
August 7, 2026
Date the Chief Executive Officer signed the report on behalf of the company
Par value per share
$0.01 per share
Par value of Aveanna Healthcare’s common stock listed on The Nasdaq Stock Market LLC
Key Terms
Class III director, independent director, Clinical Quality Committee, Emerging growth company
4 terms
Class III director regulatory
"Dr. Erica Schwartz, a Class III director of Aveanna Healthcare"
A Class III director is a board member placed in one of the numbered groups used by companies with a staggered (or “classified”) board; that director’s seat typically comes up for election in the third year of a three-year rotation. For investors this matters because staggered terms create continuity but also make it harder to replace the whole board quickly, affecting shareholder influence, takeover dynamics and how fast new strategy or accountability can be implemented — like replacing only some players on a sports team each season instead of the whole roster at once.
independent director regulatory
"Prior to her resignation, Dr. Schwartz was an independent director"
An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.
Clinical Quality Committee medical
"serving as the Chair of the Clinical Quality Committee"
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What board change did Aveanna Healthcare (AVAH) disclose in this report?
Aveanna Healthcare reported that Dr. Erica Schwartz, a Class III independent director, resigned from its Board of Directors effective August 5, 2026, following her nomination and confirmation as Director of the U.S. Centers for Disease Control and Prevention.
Why did Dr. Erica Schwartz resign from Aveanna Healthcare’s (AVAH) board?
Dr. Erica Schwartz resigned from Aveanna’s board in connection with her nomination and subsequent confirmation as Director of the U.S. Centers for Disease Control and Prevention, transitioning from a corporate governance role to a senior federal public health position.
Did Dr. Erica Schwartz cite any disagreements with Aveanna Healthcare (AVAH)?
No. Aveanna states that Dr. Schwartz’s decision to resign was not due to any disagreement with the company on matters related to its operations, policies, or practices, indicating an amicable separation tied to her new federal appointment.
What roles did Dr. Erica Schwartz hold at Aveanna Healthcare (AVAH) before resigning?
Before resigning, Dr. Schwartz served as an independent Class III director and as Chair of the Clinical Quality Committee, a board committee responsible for overseeing clinical quality and related standards within Aveanna Healthcare’s operations.
When was Aveanna Healthcare’s (AVAH) current report on this board change signed?
The report describing Dr. Schwartz’s resignation was signed on August 7, 2026 by Jeff Shaner, Aveanna Healthcare’s Chief Executive Officer and Principal Executive Officer, acting on behalf of the company.
AI-generated analysis. How Rhea-AI works. Not financial advice.
